PC
EGRX

Paulson & Co’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Paulson & Co’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-21,000
Closed -$815K – 99
2016
Q2 		$815K Buy
+21,000
New +$874K 0.01% 80

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Paulson & Co's EGRX Position: Q3 2016 in Review

Paulson & Co sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2016, closing a stake of 21,000 shares — an estimated $815K sold.

Paulson & Co first reported a position in EGRX in Q2 2016 and held it in 1 quarter. The position peaked at $815K in Q2 2016. 137 funds tracked by Wall St. Rank hold EGRX as of Q3 2016.

  • Paulson & Co reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Paulson & Co sold 21,000 Eagle Pharmaceuticals, Inc. shares in Q3 2016, an estimated $815K.
  • Paulson & Co first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • Paulson & Co's Eagle Pharmaceuticals, Inc. position peaked at $815K in Q2 2016.
  • 137 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2016.

Based on Paulson & Co's 13F filing for Q3 2016, filed 14 Nov 2016.